ClinicalTrials.gg
CompletedNCT02231008Updated Nov 18, 2022

Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS

A Phase 2/3 interventional study of tasimelteon and placebo in Smith-Magenis Syndrome and Circadian, sponsored by Vanda Pharmaceuticals. Completed at 4 sites in United States. Open to participants aged 3 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-11-18.

Sponsored by Vanda Pharmaceuticals · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
3 Years to 65 Years
Sex
All
01

Study summary

The aim of this study is to investigate tasimelteon vs. placebo on sleep disturbances of individuals with Smith-Magenis Syndrome.

02

Conditions studied

  • Smith-Magenis Syndrome
  • Circadian

Keywords

  • SMS
03

In context

Lead sponsor

Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A confirmed clinical diagnosis of SMS
  2. from the patient or the legal guardian
  3. Male or female between the ages of 3- 65 years of age
  4. Recent history of sleep disturbances
  5. Have an appointed care-giver complete the required outpatient assessments
  6. Willing and able to comply with study requirements and restrictions

Exclusion criteria

Exclusion Criteria:

  1. Unable to dose daily with medication
  2. Exposure to any drug, including placebo, within 30 days or 5 half-lives (whichever was longer) of screening
  3. Any other sound medical reason as determined by the clinical investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Tasimelteon

    Single dose oral capsule or equivalent age-appropriate oral formulation, daily dosage

    Drug: tasimelteon

  • Placebo comparator
    Placebo

    Placebo comparator

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. To determine the efficacy of tasimelteon administered daily compared to placebo, as measured by improvement in sleep parameters

    Time frame: 9 Weeks

Secondary outcomes

  1. Safety and tolerability as measured by spontaneous reporting of adverse events (AEs).

    Time frame: up to 137 weeks

07

Study locations

4 sites
  • Santa Monica, California, United States
  • Baltimore, Maryland, United States
  • Chevy Chase, Maryland, United States
  • Houston, Texas, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in Nov 2018, 38 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2014
First posted
Sep 3, 2014
StartActual
Sep 2015
Primary completionActual
Nov 19, 2018
CompletionActual
Jan 2022
Last update
Nov 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02231008
Responsible party
Sponsor
First posted
Sep 3, 2014
Start date
Sep 2015
Primary completion
Nov 19, 2018
Completion
Jan 2022
Last update
Nov 18, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tasimelteon

Start the discussion